I hope they continue with the mention of Zenith and their programs, and especially who they are working with. It really adds to the credibility of our apabetalone program when potential investors see the depth of their overall expertise - in this field of epigenetics!

Resverlogix’s sister company, Zenith Epigenetics, is using the same science to investigate treatments for multiple cancers with significant unmet medical needs. The company’s BETi, ZEN-3694 is in Phase 2 clinical development for the treatment of prostate cancer and, in collaboration with Pfizer, for breast cancer.

“Prostate cancer drugs, for example, are only good for two years because the cancer mutates around those drugs,” says McCaffrey. “Our approach is to work synergistically with pharmaceutical companies by creating treatments intended to arrest that mutation.”